Sentiment-Signal
28,1
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Travere Therapeutics, Inc. |
|---|---|
| Ticker | TVTX |
| CIK | 0001438533 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,68 Mrd. USD |
| Beta | 0,87 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 490,728,000 | -25,546,000 | -0.29 | 605,191,000 | 114,828,000 |
| 2025-09-30 | 10-Q | 164,859,000 | 25,706,000 | 0.28 | 538,581,000 | 73,564,000 |
| 2025-06-30 | 10-Q | 114,449,000 | -12,755,000 | -0.14 | 555,309,000 | 32,747,000 |
| 2025-03-31 | 10-Q | 81,732,000 | -41,226,000 | -0.47 | 548,799,000 | 32,823,000 |
| 2024-12-31 | 10-K | 233,175,000 | -321,545,000 | -4.08 | 594,125,000 | 59,077,000 |
| 2024-09-30 | 10-Q | 62,898,000 | -54,811,000 | -0.70 | 504,410,000 | -30,454,000 |
| 2024-06-30 | 10-Q | 54,116,000 | -70,409,000 | -0.91 | 551,121,000 | 15,147,000 |
| 2024-03-31 | 10-Q | 41,374,000 | -136,061,000 | -1.76 | 663,547,000 | 74,071,000 |
| 2023-12-31 | 10-K | 45,059,000 | -90,173,000 | -1.18 | 788,913,000 | 200,810,000 |
| 2023-09-30 | 10-Q | 37,095,000 | 150,735,000 | 1.97 | 832,850,000 | 279,766,000 |
| 2023-09-30 | 10-K | 37,095,000 | 150,735,000 | 1.97 | ||
| 2023-06-30 | 10-Q | 32,196,000 | -85,630,000 | -1.13 | 736,429,000 | 116,485,000 |
| 2023-06-30 | 10-K | 32,196,000 | -85,630,000 | -1.13 | ||
| 2023-03-31 | 10-Q | 30,888,000 | -86,331,000 | -1.27 | 808,231,000 | 189,140,000 |
| 2023-03-31 | 10-K | 30,888,000 | -86,331,000 | -1.27 | ||
| 2022-12-31 | 10-K | 29,339,000 | -65,823,000 | -1.03 | 672,585,000 | 42,851,000 |
| 2022-09-30 | 10-Q | 28,075,000 | -69,656,000 | -1.09 | 726,215,000 | 100,676,000 |
| 2022-09-30 | 10-K | 28,075,000 | -69,656,000 | -1.09 | ||
| 2022-06-30 | 10-K | 28,634,000 | -67,032,000 | -1.05 | ||
| 2022-06-30 | 10-Q | 54,167,000 | -67,032,000 | -1.05 | 779,494,000 | 156,713,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -9,100 | 39.09 | -355,719.00 | -73,6% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -56,815 | 41.01 | -2,329,983.15 | -482,3% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,165 | 41.75 | -299,138.75 | -61,9% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -20 | 42.66 | -853.20 | -0,2% | |
| 2026-04-15 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,018 | 42.61 | -43,376.98 | -9,0% | |
| 2026-04-15 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,014 | 42.61 | -43,206.54 | -8,9% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5,226 | 41.62 | -217,506.12 | -45,0% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -1,559 | 42.53 | -66,304.27 | -13,7% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7,215 | 41.93 | -302,516.29 | -62,6% | |
| 2026-04-14 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -21,977 | 41.07 | -902,595.39 | -186,8% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -26,000 | 41.07 | -1,067,820.00 | -221,0% | |
| 2026-04-14 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -7,215 | 41.93 | -302,516.29 | -62,6% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -6,750 | 42.12 | -284,310.00 | -58,8% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7,239 | 41.93 | -303,522.58 | -62,8% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9 | 41.07 | -369.63 | -0,1% | |
| 2026-04-14 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7,215 | 41.93 | -302,516.29 | -62,6% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -37,500 | 41.07 | -1,540,125.00 | -318,8% | |
| 2026-04-14 | LYONS GARY A | Director | Open Market Sale | -8,000 | 41.07 | -328,560.00 | -68,0% | |
| 2026-04-13 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -65 | 28.85 | -1,875.25 | -0,4% | |
| 2026-04-06 | Baynes Roy D. | Director | Open Market Sale | -10,000 | 33.00 | -330,000.00 | -68,3% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -34,902 | 30.55 | -1,066,256.10 | -220,7% | |
| 2026-04-01 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10,000 | 30.00 | -300,000.00 | -62,1% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -25,098 | 31.46 | -789,583.08 | -163,4% | |
| 2026-03-16 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10,000 | 28.09 | -280,861.00 | -58,1% | |
| 2026-02-20 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -60,000 | 30.10 | -1,805,766.00 | -373,8% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -4,321 | 28.26 | -122,120.10 | -25,3% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5,679 | 27.50 | -156,195.22 | -32,3% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -509 | 32.74 | -16,664.66 | -3,4% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2,485 | 32.07 | -79,693.95 | -16,5% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -110 | 32.90 | -3,619.00 | -0,7% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,635 | 32.14 | -52,548.90 | -10,9% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -232 | 32.85 | -7,621.20 | -1,6% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,547 | 32.11 | -49,674.17 | -10,3% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -66,452 | 32.06 | -2,130,451.12 | -441,0% | |
| 2026-02-03 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7,175 | 32.12 | -230,461.00 | -47,7% | |
| 2026-02-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7,242 | 32.12 | -232,613.04 | -48,1% | |
| 2026-02-03 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6,956 | 32.12 | -223,426.72 | -46,2% | |
| 2026-02-03 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7,310 | 32.12 | -234,797.20 | -48,6% | |
| 2026-02-03 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -12,446 | 32.87 | -409,100.02 | -84,7% | |
| 2026-02-03 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -4,333 | 32.12 | -139,175.96 | -28,8% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -33,635 | 32.70 | -1,099,864.50 | -227,7% | |
| 2026-01-27 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -51,865 | 30.10 | -1,560,980.91 | -323,1% | |
| 2026-01-23 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -8,135 | 30.01 | -244,153.31 | -50,5% | |
| 2026-01-20 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10,000 | 27.34 | -273,420.00 | -56,6% | |
| 2026-01-06 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -445 | 37.75 | -16,798.75 | -3,5% | |
| 2026-01-05 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2,031 | 40.18 | -81,605.58 | -16,9% | |
| 2025-12-24 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -15,000 | 42.00 | -630,004.50 | -130,4% | |
| 2025-12-24 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -7,402 | 40.00 | -296,080.00 | -61,3% | |
| 2025-12-24 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -60,000 | 40.10 | -2,406,180.00 | -498,1% | |
| 2025-12-24 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -4,980 | 40.00 | -199,200.00 | -41,2% | |
| 2025-12-15 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -2,910 | 36.00 | -104,760.00 | -21,7% | |
| 2025-12-01 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -20,000 | 35.01 | -700,202.00 | -144,9% | |
| 2025-11-04 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -67,115 | 36.00 | -2,416,140.00 | -500,1% | |
| 2025-10-31 | Coughlin Timothy | Director | Open Market Sale | -18,000 | 35.03 | -630,601.20 | -130,5% | |
| 2025-10-31 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -5,591 | 35.00 | -195,685.00 | -40,5% | |
| 2025-10-29 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -27,128 | 30.12 | -817,073.66 | -169,1% | |
| 2025-10-28 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -2,662 | 30.00 | -79,860.00 | -16,5% | |
| 2025-10-28 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -92,872 | 30.38 | -2,821,358.49 | -584,0% | |
| 2025-09-22 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10,000 | 25.00 | -250,000.00 | -51,7% | |
| 2025-09-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -119 | 19.71 | -2,345.49 | -0,5% | |
| 2025-09-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -454 | 18.20 | -8,262.80 | -1,7% | |
| 2025-08-27 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -470 | 17.31 | -8,135.70 | -1,7% | |
| 2025-07-01 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -815 | 14.65 | -11,939.75 | -2,5% | |
| 2025-05-05 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -1,771 | 21.05 | -37,279.55 | -7,7% | |
| 2025-05-05 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -18,924 | 21.05 | -398,350.20 | -82,5% | |
| 2025-05-05 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -4,920 | 21.05 | -103,566.00 | -21,4% | |
| 2025-05-05 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -3,198 | 21.05 | -67,317.90 | -13,9% | |
| 2025-05-05 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,784 | 21.05 | -37,553.20 | -7,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.